CD200 R1

CD200 R1

CD200 R1 Overview

Molecule Name
Cell surface glycoprotein CD200 receptor 1
Synonyms
CD200R,CRTR2,MOX2R,OX2R
Drug Development Progress
Drugs in Clinical Trials4
Approved Drugs0
Highest Development StagePhase 2 Clinical
Target Synonym
Cell surface glycoprotein OX2 receptor 1,CD200 cell surface glycoprotein receptor,CD200R
Background
Cell surface glycoprotein CD200 receptor 1 is a protein that in humans is encoded by the CD200R1 gene. This gene encodes a receptor for the OX-2 membrane glycoprotein. Both the receptor and substrate are cell surface glycoproteins containing two immunoglobulin-like domains. This receptor is restricted to the surfaces of myeloid lineage cells and the receptor-substrate interaction may function as a myeloid downregulatory signal. CD200 and its receptor CD200R are both type-1 membrane glycoproteins, which are members of the immunoglobulin superfamily (IgSF). Besides the inhibitory effect on macrophages, CD200/CD200R also play an important role in regulating the regulatory T cells, allergicreaction, autoimmune diseases, allograft, neurological diseases and other autoimmune-related diseases. The interaction between CD200, which is mainly present in neurons but also in astrocytes, and CD200R1, which is mainly present in microglia, is one of the mechanisms involved in keeping the microglial proinflammatory phenotype under control in physiological conditions. Alterations in the expression of CD200 and CD200R1 have been described in neurodegenerative diseases, but little is known about the mechanism of regulation of these proteins under physiological or pathological conditions.

CD200 R1 Product List

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Project Cooperation

Project NameDrug TypeTherapeutic AreaIndicationStageRights Area
High selective OX1R/OX2R dual inhibitor treating insomniaSmall moleculeNeurological diseaseInsomniaPhase IGlobal
Drug Type
Small molecule
Therapeutic Area
Neurological disease
Indication
Insomnia
Stage
Phase I
Rights Area
Global